These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 37062502

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage.
    Sato T, Sato C, Kadowaki A, Watanabe H, Ho L, Ishida J, Yamaguchi T, Kimura A, Fukamizu A, Penninger JM, Reversade B, Ito H, Imai Y, Kuba K.
    Cardiovasc Res; 2017 Jun 01; 113(7):760-769. PubMed ID: 28371822
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [The functional role of endogenous APJ agonists; Apelin and Elabela/Toddler in cardiovascular diseases].
    Sato T, Kuba K.
    Nihon Yakurigaku Zasshi; 2019 Jun 01; 153(4):172-178. PubMed ID: 30971657
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The biological function of ELABELA and APJ signaling in the cardiovascular system and pre-eclampsia.
    Liu Y, Wang L, Shi H.
    Hypertens Res; 2019 Jul 01; 42(7):928-934. PubMed ID: 30626933
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. APJ acts as a dual receptor in cardiac hypertrophy.
    Scimia MC, Hurtado C, Ray S, Metzler S, Wei K, Wang J, Woods CE, Purcell NH, Catalucci D, Akasaka T, Bueno OF, Vlasuk GP, Kaliman P, Bodmer R, Smith LH, Ashley E, Mercola M, Brown JH, Ruiz-Lozano P.
    Nature; 2012 Aug 16; 488(7411):394-8. PubMed ID: 22810587
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The Elabela-APJ axis: a promising therapeutic target for heart failure.
    Ma Z, Song JJ, Martin S, Yang XC, Zhong JC.
    Heart Fail Rev; 2021 Sep 16; 26(5):1249-1258. PubMed ID: 32314083
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Elabela-apelin-12, 17, 36/APJ system promotes platelet aggregation and thrombosis via activating the PANX1-P2X7 signaling pathway.
    Chen Z, Luo X, Liu M, Jiang J, Li Y, Huang Z, Wang L, Cao J, He L, Huang S, Hu H, Li L, Chen L.
    J Cell Biochem; 2023 Apr 16; 124(4):586-605. PubMed ID: 36855998
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Apelin/APJ system as a therapeutic target in diabetes and its complications.
    Hu H, He L, Li L, Chen L.
    Mol Genet Metab; 2016 Sep 16; 119(1-2):20-7. PubMed ID: 27650065
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.